This article was originally published in The Tan Sheet
Firm's net sales increase 7.6% to $58.4 mil., with earnings up 118.8% to $3.1 mil. in the first quarter (ended March 31). Mannatech attributes the results to "building momentum" from new and existing associates and members. The firm's sales associates brought 141,000 new customers in the 12 months ended March 31, according to CEO Samuel Caster. Mannatech plans to launch products in South Korea in the third quarter and roll out Ambrotose AO in the United Kingdom, Japan, Australia and New Zealand later this year...
You may also be interested in...
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
As agency implements testing contract for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.